← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV21행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTPhase 2
Interferon-alpha (Interferon-alpha)
Merck Sharp & Dohme LLC·Lymphoproliferative Disorder
59 trials
Overview
Program
Interferon-alpha
Overview
Company
Merck Sharp & Dohme LLC
Overview
Modality
CGT
Overview
Target
Lymphoproliferative Disorder
Overview
Indication
Lymphoproliferative Disorder; HHV-8
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
MoA
Mechanism
targeting chimeric antigen receptor
MoA
Biomarker
biomarkers
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse, In vitro
PK/PD
Experiment
PD
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse, In vitro
Toxicology
Major finding
A yellow fever 17D and Usutu virus chimera with rationally designed mutations in the envelope protein is lethal in an Ifnar -/- mouse model.. The expanding geographical spread of Usutu virus (USUV) poses an increasing threat to bird populations and to human health. Here we assessed a chimeric USUV vaccine candidate that was constructed using the live attenuated yellow fever virus (YFV) YF-17D plat…
Toxicology
CRS
Reported
Clinical
OS
56
Clinical
Result source
ClinicalTrials.gov NCT00006237
Clinical
Data Tier / Score
A · 38
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 13일 (1일 전)